PMG 1015
Alternative Names: PMG-1015Latest Information Update: 15 Jun 2026
At a glance
- Originator Pulmongene
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action MDK protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 27 Sep 2025 Efficacy, adverse events and pharmacokinetics data from a phase Ib trial in Idiopathic pulmonary fibrosis presented at the 35th Annual Congress of the European Respiratory Society (ERS-2025)
- 17 May 2025 PMG 1015 is still in phase I trials for Idiopathic pulmonary fibrosis (IPF) (In volunteers) in Australia.
- 17 May 2025 Adverse events and pharmacokinetics pooled analysis data from a two phase Ia trial in healthy volunteers presented 121st International Conference of the American Thoracic Society (ATS 2025)